Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Int J Infect Dis ; 129: 40-48, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36682681

RESUMEN

OBJECTIVES: To determine whether hydroxychloroquine (HCQ) is safe and effective at preventing COVID-19 infections among health care workers (HCWs). METHODS: In a 1: 1 randomized, placebo-controlled, double-blind, parallel-group, superiority trial at 34 US clinical centers, 1360 HCWs at risk for COVID-19 infection were enrolled between April and November 2020. Participants were randomized to HCQ or matched placebo. The HCQ dosing included a loading dose of HCQ 600 mg twice on day 1, followed by 400 mg daily for 29 days. The primary outcome was a composite of confirmed or suspected COVID-19 clinical infection by day 30, defined as new-onset fever, cough, or dyspnea and either a positive SARS-CoV-2 polymerase chain reaction test (confirmed) or a lack of confirmatory testing due to local restrictions (suspected). RESULTS: Study enrollment closed before full accrual due to recruitment challenges. The primary end point occurred in 41 (6.0%) participants receiving HCQ and 53 (7.8%) participants receiving placebo. No difference in the proportion of participants experiencing clinical infection (estimated difference of -1.8%, 95% confidence interval -4.6-0.9%, P = 0.20) was identified nor any significant safety issues. CONCLUSION: Oral HCQ taken as prescribed appeared safe among HCWs. No significant clinical benefits were observed. The study was not powered to detect a small but potentially important reduction in infection. TRIAL REGISTRATION: NCT04334148.


Asunto(s)
COVID-19 , Profilaxis Pre-Exposición , Humanos , COVID-19/prevención & control , SARS-CoV-2 , Hidroxicloroquina/efectos adversos , Tratamiento Farmacológico de COVID-19 , Personal de Salud , Resultado del Tratamiento
2.
IDCases ; 29: e01568, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35855941

RESUMEN

Obstetric tetanus is defined as a C. tetani infection that occurs during pregnancy or within six weeks of delivery. In Peru, there are no reports of obstetric tetanus cases. Here we report a sixth case of obstetric tetanus in a puerperal woman who underwent curettage for postpartum hemorrhage, despite immunization against tetanus.

3.
Med Mycol Case Rep ; 33: 21-25, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34295641

RESUMEN

The standard of care for treatment of sino-orbital mucormycosis involves aggressive surgical debridement and liposomal amphotericin, and the roles of adjunctive and topical therapies are less clear. Here we describe a case of severe refractory sino-orbital mucormycosis in an immunocompetent patient who responded to combination therapy with liposomal amphotericin, isavuconazole, micafungin, and topical amphotericin deoxycholate after failing to achieve negative surgical margins.

4.
Proc (Bayl Univ Med Cent) ; 32(4): 574-576, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31656425

RESUMEN

Pasteurella multocida is a bipolar staining gram-negative coccobacillus that resides in the nasopharynx of many animals, most notably felines. It is a common cause of soft tissue infections following animal bites but has rarely been reported to cause epiglottitis. Here we describe a case of epiglottitis and bacteremia due to P. multocida following exposure to a feral cat. The patient required emergent cricothyrotomy due to airway compromise. He was successfully treated with 14 days of beta-lactam therapy and achieved a full recovery.

5.
IDCases ; 18: e00612, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31463196

RESUMEN

Cryptococcus species (other than Cryptococcus neoformans) have been labeled as saprophytic and nonpathogenic in immunocompetent individuals in the past. In recent years, infections caused by non-neoformans Cryptococcus species have been recognized. Cryptococcus laurentii is known to be a rare human pathogen. In this case report, we present a 59-year-old man who did not have HIV infection with meningoencephalitis caused by Cryptococcus laurentii. No significant underlying immunosuppressive disorder was found. The only identifiable risk factors were that the patient was a farmer with previous exposure to pigeon droppings. Here, we describe what we believe to be the fifth reported case of meningitis caused by Cryptococcus laurentii.

6.
Adv Chronic Kidney Dis ; 26(1): 35-40, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30876615

RESUMEN

Patients with chronic kidney disease have impaired immunity that increases their risk of infection. Increased incidence of mycobacterial infections, in particular Mycobacterium tuberculosis, is described in patients undergoing hemodialysis and peritoneal dialysis as well as after kidney transplantation in low-prevalence and high-prevalence settings. Diagnosis of this infection can be challenging because of atypical presentations that may lead to treatment delay and, consequently, increased mortality; however, recent advances in molecular testing have improved diagnostic accuracy. It is imperative to try to identify those patients at increased risk and offer adequate prophylaxis. There are controversies and insufficient data regarding treatment agents, duration, and dosages. Most studies in nontuberculous mycobacteria are based on case series and retrospective studies.


Asunto(s)
Antituberculosos/uso terapéutico , Fallo Renal Crónico/terapia , Trasplante de Riñón , Tuberculosis Latente/tratamiento farmacológico , Infecciones por Mycobacterium no Tuberculosas/tratamiento farmacológico , Humanos , Ensayos de Liberación de Interferón gamma , Fallo Renal Crónico/epidemiología , Tuberculosis Latente/diagnóstico , Tuberculosis Latente/epidemiología , Infecciones por Mycobacterium no Tuberculosas/diagnóstico , Infecciones por Mycobacterium no Tuberculosas/epidemiología , Diálisis Peritoneal , Peritonitis Tuberculosa/diagnóstico , Peritonitis Tuberculosa/tratamiento farmacológico , Peritonitis Tuberculosa/epidemiología , Diálisis Renal , Insuficiencia Renal Crónica/epidemiología , Tuberculosis/diagnóstico , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Tuberculosis Ganglionar/diagnóstico , Tuberculosis Ganglionar/tratamiento farmacológico , Tuberculosis Ganglionar/epidemiología
7.
J Med Microbiol ; 67(1): 83-86, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29154747

RESUMEN

INTRODUCTION: When clinicians think about Staphylococcus aureus bacteria, what comes to the mind of most is the dreaded methicillin-resistant form. However, clinicians should not forget the methicillin-susceptible type, which is just as virulent. CASE PRESENTATION: The authors present the case of a 20-year-old woman who was admitted with septic shock and multi-organ failure and was found to have disseminated methicillin-susceptible Staphylococcus aureus (MSSA) infection. The patient had persistent blood cultures positive for MSSA. A transesophageal echocardiogram showed a 1.1 cm vegetation in the mitral valve, and the patient had bilateral pleural effusions that grew MSSA. An MRI of the brain showed multiple areas consistent with infarctions thought to be secondary to septic emboli. The patient underwent a mitral valve replacement and was treated with a prolonged course of parenteral nafcillin. DISCUSSION: This case illustrates a severe clinical presentation and management of MSSA infections.


Asunto(s)
Meticilina/farmacología , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/aislamiento & purificación , Adulto , Antibacterianos/uso terapéutico , Femenino , Humanos , Nafcilina/uso terapéutico , Infecciones Estafilocócicas/diagnóstico , Staphylococcus aureus/efectos de los fármacos , Adulto Joven
8.
J Infect ; 67(4): 265-72, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23769840

RESUMEN

OBJECTIVE: To determine the diagnostic yield of skin biopsy in patients with leukemia, new skin lesions, and suspected infection. METHODS: We reviewed the medical records of all patients with leukemia who underwent skin biopsy for new lesions and clinical suspicion of infection over 4 years. Biopsy was considered to have changed the diagnosis, if the results differed from the prior leading clinical impression. RESULTS: Seventy-six (39%) of 195 patients had infections identified via skin biopsy. Among the remaining patients, the most common diagnoses were leukemia cutis, drug reactions and Sweet's syndrome. Ulcerated or necrotic lesions and bacteremia or fungemia were the only independent predictors of infection. 55% of patients with severe neutropenia had biopsy-proven infectious causes of their skin lesions. One third of all afebrile patients had skin manifestations owing to infection. Skin biopsy results differed from the initial clinical impression in 34% of all patients. In 45% of infected patients, pathogens were identified by skin biopsy alone. CONCLUSIONS: Noninfectious causes accounted for a large proportion of new skin lesions in leukemia patients with suspected infections. Absence of neutropenia or fever did not rule out infection. Ulcerated or necrotic lesions and bacteremia or fungemia were independent predictors of infection. In the evaluation of patients with leukemia and new skin lesions, skin biopsy remains an important procedure to rule out infection, and is particularly useful for pathogen identification.


Asunto(s)
Biopsia/métodos , Enfermedades Transmisibles/diagnóstico , Leucemia/complicaciones , Piel/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven
9.
Med Mycol ; 50(5): 543-8, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22103347

RESUMEN

There have been no published studies evaluating the efficacy and safety of weekly liposomal amphotericin B as secondary prophylaxis in leukemic patients with invasive fungal infections (IFIs). We found in a retrospective review of our experience with 14 such patients admitted from 2003-2009 that the use of this approach was associated with frequent relapse of IFIs (36%) and kidney injury (36%).


Asunto(s)
Profilaxis Antibiótica , Antifúngicos/uso terapéutico , Neoplasias Hematológicas/complicaciones , Micosis/tratamiento farmacológico , Adulto , Anciano , Anfotericina B/administración & dosificación , Anfotericina B/uso terapéutico , Antifúngicos/administración & dosificación , Femenino , Humanos , Leucemia/complicaciones , Masculino , Persona de Mediana Edad , Micosis/complicaciones , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...